Pharming Group N.V. (PHGUF)
OTCMKTS · Delayed Price · Currency is USD
2.150
+0.300 (16.22%)
At close: Jan 27, 2026
Pharming Group Employees
Pharming Group had 404 employees as of December 31, 2024. The number of employees increased by 22 or 5.76% compared to the previous year.
Employees
404
Change (1Y)
22
Growth (1Y)
5.76%
Revenue / Employee
$896,718
Profits / Employee
$946
Market Cap
1.06B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 404 | 22 | 5.76% |
| Dec 31, 2023 | 382 | 50 | 15.06% |
| Dec 31, 2022 | 332 | 55 | 19.86% |
| Dec 31, 2021 | 277 | 15 | 5.73% |
| Dec 31, 2020 | 262 | 50 | 23.58% |
| Jan 1, 2020 | 212 | 29 | 15.85% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Pharming Group News
- 6 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - PRNewsWire
- 8 days ago - Pharming Group: Crossing From Speculation To Profitability - Seeking Alpha
- 8 days ago - Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript - Seeking Alpha
- 10 days ago - FDA Strikes Off European Biotech Pharming's Immune Deficiency Drug For Expanded Use In Pediatric Patients - Benzinga
- 10 days ago - FDA Refuses To Approve Expanded Use Of Pharming's Joenja In Children With APDS - Nasdaq
- 10 days ago - Pharming Group (PHAR) Schedules Virtual Investor Day for February - GuruFocus
- 10 days ago - Pharming Group Receives FDA Complete Response Letter For Joenja Pediatric SNDA - Nasdaq
- 10 days ago - Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS - GlobeNewsWire